ROIVANT SCIENCES
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.
ROIVANT SCIENCES
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Product Research
Founded:
2014-05-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.roivant.com
Total Employee:
501+
Status:
Active
Total Funding:
2.09 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Global Site Tag Nginx Amazon
Current Advisors List
Board_member
2021-10-01
Current Employees Featured
Vivek Ramaswamy Founder and Executive Chairman @ Roivant Sciences
Founder and Executive Chairman
2014-01-01
Mayukh Sukhatme Chief Investment Officer & President @ Roivant Sciences
Chief Investment Officer & President
2015-01-01
Benjamin Zimmer President, Roivant Health @ Roivant Sciences
President, Roivant Health
Frank Torti Vant Chair @ Roivant Sciences
Vant Chair
2018-01-01
Matthew Gline Chief Executive Officer @ Roivant Sciences
Chief Executive Officer
2021-01-01
Dan Rothman Chief Information Officer @ Roivant Sciences
Chief Information Officer
2017-04-01
Celine Chan Chief Information Security Officer @ Roivant Sciences
Chief Information Security Officer
2022-04-01
Eric Venker Chief Operating Officer @ Roivant Sciences
Chief Operating Officer
2018-01-01
Drew Fromkin Chief Executive Officer Proteovant, Vant Portfolio Operating Partner (Roivant Sciences) @ Roivant Sciences
Chief Executive Officer Proteovant, Vant Portfolio Operating Partner (Roivant Sciences)
2021-01-01
Raheleh Hatami Associate, Investments @ Roivant Sciences
Associate, Investments
2018-04-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-02-26 | Silicon Therapeutics | Silicon Therapeutics acquired by Roivant Sciences | 450 M USD |
Investors List
Eventide
Eventide investment in Post-IPO Equity - Roivant Sciences
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Post-IPO Equity - Roivant Sciences
Viking Global Investors
Viking Global Investors investment in Post-IPO Equity - Roivant Sciences
RTW Investments LLC
RTW Investments LLC investment in Post-IPO Equity - Roivant Sciences
Patient Square Capital
Patient Square Capital investment in Post-IPO Equity - Roivant Sciences
Palantir Technologies
Palantir Technologies investment in Post-IPO Equity - Roivant Sciences
Dainippon Sumitomo Pharma
Dainippon Sumitomo Pharma investment in Post-IPO Equity - Roivant Sciences
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Roivant Sciences
SoftBank Capital
SoftBank Capital investment in Post-IPO Equity - Roivant Sciences
Novaquest Capital Management
Novaquest Capital Management investment in Private Equity Round - Roivant Sciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-11-03 | Medallion | Roivant Sciences investment in Series B - Medallion | 30 M USD |
| 2021-11-01 | gen-t | Roivant Sciences investment in Pre Seed Round - gen-t | 2 M USD |
| 2021-08-02 | Immunovant | Roivant Sciences investment in Post-IPO Equity - Immunovant | 200 M USD |
| 2020-10-08 | Datavant | Roivant Sciences investment in Series B - Datavant | 40 M USD |
| 2018-04-30 | Datavant | Roivant Sciences investment in Venture Round - Datavant | 40.5 M USD |
| 2017-10-02 | Arbutus Biopharma | Roivant Sciences investment in Post-IPO Equity - Arbutus Biopharma | 116.4 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-02 | Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation |
Official Site Inspections
http://www.roivant.com Semrush global rank: 836.93 K Semrush visits lastest month: 45.72 K
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Roivant Sciences"
Corporate Responsibility | Roivant
Roivant Social Ventures (RSV), a 501(c)3 social impact organization created by Roivant in 2020, envisions a future where every person is born with the right and ability to access medicine and medical care. RSV partners with innovative …See details»
Roivant
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to …See details»
Roivant Sciences - Wikipedia
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of BostonSee details»
Roivant Sciences - Crunchbase Company Profile
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. Roivant’s mission is to …See details»
Roivant - LinkedIn
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology ...See details»
Roivant Sciences | White Rose Wiki
¶Roivant Sciences. Roivant Sciences is an American-Swiss pharmaceutical and biotechnology company based in New York City, with offices in Boston, Massachusetts and Basel, …See details»
Roivant Sciences - The Org
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives of patients. Industries. Biotechnology. Headquarters. New York, United States. Employees. 201-500. …See details»
Roivant Sciences: Reinventing what a large pharma …
May 7, 2019 Instead of a single and centralized organization, we are building the ‘Alphabet of Healthcare’; a decentralized family of companies working to improve the process of developing and delivering medicines to patients. Each …See details»
Roivant Sciences - Contacts, Employees, Board Members
Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients. ... Experience the new Crunchbase, powered by AI . …See details»
Leadership | Roivant - Roivant Sciences
Alex Gasner serves as the Executive Vice President of Roivant Health, where he leads new investments and company creation in healthtech. Mr. Gasner joined Roivant in November, 2017, and previously served as Head of Corporate …See details»
How Does Roivant Work? - by Adu Subramanian
Jan 14, 2025 They seem to work best as a “Late Stage Contract Research organization”. Roivant swoops in when pharma has a good asset but lacks the resources and focus to …See details»
Immunovant Announces Next Phase of Growth with Roivant …
Apr 21, 2025 Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune …See details»
Roivant Provides Corporate Updates | Roivant Sciences Ltd.
Jun 9, 2021 Datavant and Ciox Health have signed a definitive merger agreement Combined company positioned to solve the challenge of health data fragmentation Additional Roivant …See details»
Roivant Sciences - Wikiwand
Roivant is a major shareholder of Datavant, which was co-founded with Travis May to link disparate healthcare datasets. [43] In October 2020, Datavant announced it raised funds from …See details»
Immunovant narrows R&D focus as Roivant execs join C-suite
Apr 21, 2025 Against that backdrop, Roivant has announced that its president and chief operating officer, Eric Venker, M.D., is taking over as CEO of Immunovant. Pete Salzmann, …See details»
Careers | Roivant
Our culture is rooted in innovation and inspired by non-linear career trajectories, allowing for an array of career paths with sustained professional growth within the Roivant family of …See details»
Immunovant replaces CEO, makes other changes as Roivant …
Apr 21, 2025 Immunovant was spun out of Roivant in 2019 to develop a pipeline of drugs to treat autoimmune disorders. While Immunovant is its own publicly traded entity, Roivant retains …See details»
Roivant Sciences Ltd. (ROIV): history, ownership, mission, how it …
[relinking] Home History Owners Mission How It Works How It Makes Money Roivant Sciences Ltd. (ROIV) Information A Brief History of Roivant Sciences Ltd. (ROIV) Company Overview …See details»
Immunovant Announces Next Phase of Growth with Roivant …
Apr 21, 2025 Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune …See details»
roivant.com Reviews: Is this site a scam or legit?
Roivant.com Review. The Scam Detector website Validator gives roivant.com one of the higher trust scores on the platform: 86.It signals that the business is best defined by the following …See details»